Objective-The goal of this study was to define and characterize the subpopulation of platelets capable of regulating the functional interactions of factors Va (FVa) and Xa (FXa) on the thrombin-activated platelet surface. Methods and Results-Flow cytometric analyses were used to define and characterize platelet subpopulations. At a concentration of thrombin known to elicit maximal platelet activation, platelet-derived FVa release, and prothrombinase assembly/function, only a subpopulation of platelets was positive for FVa and FXa binding. An additional subpopulation bound lower levels of FVa but little, if any, FXa. Fluorescence microscopy analyses confirmed these data.
T hrombin generation is pivotal to many physiological and pathophysiologic processes, including but not limited to hemostasis, 1 thrombosis, 1 wound healing, 2 and atherosclerosis. 3 Thrombin is formed via prothrombinase, a Ca 2ϩdependent, stoichiometric complex of the cofactor factor Va (FVa) and the serine protease factor Xa (FXa), assembled on an appropriate membrane surface. 1 Even though FXa effects the cleavage of prothrombin to thrombin, its ability to do so in a physiologically relevant time frame is absolutely dependent on the presence of both FVa and the membrane surface. Activated platelets not only provide this membrane surface in vivo but also express and release FVa. 4 The platelet-derived pool of FVa originates from megakaryocyte endocytosis of the plasma-derived procofactor. 5, 6 Subsequent to its endocytosis, FV is phenotypically modified 7 to produce a cofactor with increased and sustained procoagulant activity, distinguishing it from its plasma-derived counterpart. 8, 9 The amount of thrombin produced via prothrombinase assembled on the surface of activated platelets is dependent on both the level of platelet activation, 10 which is defined by the agonist used, and the quantity and quality of bound FVa. Although it has long been known that platelets are heteroge-neous with respect to volume, density, lipid peroxidation, and metabolism, 11, 12 heterogeneity in the ability of activated platelets to bind coagulation factors has only recently been observed. [13] [14] [15] [16] [17] [18] [19] Alberio et al were the first to demonstrate that only a fraction of platelets activated simultaneously with low concentrations of thrombin (Ͻ5 nmol/L) and convulxin, an agonist of the collagen receptor glycoprotein (GP) VI retain high levels of platelet-derived FV/FVa at their membrane surface 13 in a transglutaminase-dependent manner. 15 Studies done by Kempton et al 16 demonstrate the formation of 2 subpopulations of activated platelets differentiated by their ability to bind the constituents of both intrinsic tenase and prothrombinase. Subsequent studies by Panteleev et al demonstrated that a unique platelet subpopulation, formed subsequent to thrombin-induced activation, binds high levels of FIXa, FVIIIa, and FX. 17 Even though all of these studies have described heterogeneity in the ability of activated platelet subpopulations to bind coagulation factors, these subpopulations have not been characterized extensively regarding their ability to generate thrombin via assembly of a functional prothrombinase or their expression of other membrane properties important for platelet function. In contrast to previous studies using lowdose thrombin and convulxin/collagen as platelet agonists, thrombin was used as the sole agonist in this study as it has been shown to effect maximal prothrombinase assembly and function at the activated platelet surface. Our data indicate that subsequent to thrombin-catalyzed activation, not all platelet-bound FVa molecules are capable of supporting FXa binding. Rather, the ability of activated platelets to generate thrombin via prothrombinase is defined by a subpopulation of platelets expressing both nondissociable and dissociable pools of platelet-derived FVa, each capable of binding FXa, and expressing an increased density of adhesive receptors at their activated membrane surface. Because the adherent properties of platelets and their ability to mount and sustain a procoagulant response are crucial steps in effecting normal hemostasis as well as pathological thrombus formation, the identified platelet subpopulation should be significant in regulating and contributing to these processes.
Methods
Materials purchased, antibody descriptions, preparation of coagulation proteins, and methods with which we have substantial experience are detailed in the supplemental materials (available online at http://atvb.ahajournals.org). Techniques and protocols new to our laboratory and essential to this work are detailed here.
Generation and Characterization of Procoagulant Platelet Subpopulations
Platelets were isolated from human venous blood collected from healthy, nonmedicated individuals as detailed previously. 20 Washed platelets (1ϫ10 8 /mL) were activated with thrombin (50 nmol/L) in the presence of Arg-Gly-Asp-Ser (RGDS 1 mmol/L) to prevent platelet aggregation. Alternatively, platelets were activated with a combination of low-dose thrombin (5 nmol/L) and convulxin (0.5 g/mL). In some experiments, platelets were activated in the presence of dansylcadaverine (Յ200 mol/L). Following the addition of hirudin (75 nmol/L), activated platelets were incubated with FXa (5 nmol/L). In some experiments, plasma-derived FVa (5 nmol/L) was also added to ensure saturation of all available prothrombinase sites. Following fixation to cross-link platelet-bound FVa and FXa, platelets expressing FVa, FXa, P-selectin, integrin ␤ 3 , GPIb␣, or integrin ␣ IIb were visualized by flow cytometry using specific or control fluorophore-conjugated monoclonal antibodies. In some experiments, the platelets were incubated with Retic-COUNT thiazole orange (TO) reagent before flow cytometric analyses. Platelet-bound proteins were also visualized by fluorescence microscopy. Flow cytometry and fluorescence microscopy protocols are detailed in the supplemental materials.
Determination of a Functional, Nondissociable, Platelet-Derived FVa Pool
Platelet suspensions (1ϫ10 9 /mL) containing RGDS (5 mmol/L) and Gly-Pro-Arg-Pro (2 mmol/L) were activated with thrombin (50 nmol/L). CaCl 2 was omitted from the buffer to disrupt Ca 2ϩdependent interactions between the FVa heavy and light chains. The platelets were subsequently washed by centrifugation 1 to 5 times in buffer containing RGDS (5 mmol/L) and lacking Ca 2ϩ . At each wash, platelet-bound FVa activity was determined using a 1-stage FV clotting assay, and retention of the FVa light and heavy chains was assessed by Western blotting. In other experiments, retention of the FVa heavy chain was assessed by flow cytometry. Details are provided in the supplemental materials.
Statistical Analyses
For Tables 1 and 2, unpaired t tests were used to calculate 2-tail probability values. All calculations were performed using GraphPad Prism software. Data are expressed as meanϮSEM.
Results

FXa Binding Defines a Unique, Procoagulant Platelet Subpopulation Dependent on but Not Described by FVa Binding
In the current study, thrombin was used at a concentration (50 nmol/L) previously shown to elicit a number of activationdependent events regulating prothrombinase assembly and function. 21 Under these conditions, the maximal release, activation, and binding of platelet-derived FVa is effected. 10 However, as the concentration of the platelet-derived cofactor is not sufficient to saturate all prothrombinase binding sites, the addition of purified plasma-derived FVa is required. When bound to the activated platelet membrane, both cofactor pools support the subsequent binding of FXa. Previously reported kinetic analyses of thrombin generation at the activated platelet membrane confirmed that human platelets, in the presence of exogenous FVa and FXa, become functionally saturated with FVa and FXa when activated with approximately 50 nmol/L thrombin. 10 In this study, even though the kinetics of prothrombin activation indicated that saturation of the platelet prothrombinase binding sites had been achieved, flow cytometric analyses indicated that only a subset of the activated platelets were able to bind FVa and FXa ( Figure 1A ). Representative analyses demonstrated that FVa binding to maximally activated platelets ( Figure 1A , upper panel) segregates into 3 distinct subpopulations: those FXa binding and platelet adhesion receptor expression were detected using appropriate fluorophore-conjugated monoclonal antibodies as described in Methods and shown in Figure 2 . Fold increases in receptor density were determined as the ratio of mean fluorescence intensity (MFI) in the FXa-positive platelets to MFI in the FXa-negative platelets. Values are expressed as meanϮSEM, nϭ2 to 109. *PϽ0.01; †PϽ0.001; ‡PϽ0.02 compared with FXa-negative platelets. Platelet adhesion receptor density was determined as described. Platelet age was assessed in all samples by analysis of TO staining as detailed in Methods. Fold increases in receptor density were determined as the ratio of mean fluorescence intensity (MFI) in the young (TO-positive) platelets to MFI in the mature (TO-negative) platelets. Values are expressed as meanϮSEM, nϭ26 to 52. *PϽ0.001 compared with mature platelets.
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demonstrating no binding (I), an intermediate level of binding (II), or substantial (ie, high) FVa binding (III). The mean fluorescence intensity of the platelets binding "intermediate" levels of FVa was consistently 5% to 8% of that expressed by those platelets binding "high" levels of FVa (5.8Ϯ1.5%, nϭ28). In duplicate reaction mixtures, assessment of FXa binding characteristics ( Figure 1A , lower panel) indicated that platelets segregate into only 2 populations: those demonstrating substantial FXa binding (III) and those demonstrating no binding whatsoever (I). Similar analyses, with 28 different platelet donors (aged 33 to 91 years old; 54% female), indicated that the percentage of platelets capable of binding FXa varied from 8% to 65% (meanϭ31.1Ϯ14.7%) (Supplemental Figure I) and was comparable to the subset defined by high FVa binding (meanϭ33.5Ϯ13.6%) for each individual. Neither donor gender nor donor age showed a correlation with the percentage of platelets comprising the procoagulant subpopulation. As the monoclonal antibodies against both FVa and FXa had the same fluorescence-toprotein ratio and yielded similarly sized subpopulations, it appears that those platelets defined as high binders may bind FVa and FXa equivalently.
To determine whether the platelets capable of high FVa binding comprised the same platelet subpopulation as those capable of binding FXa, 2 approaches were taken. FXa binding defines a unique procoagulant platelet subpopulation dependent on but not described by FVa binding. Washed platelets were activated with thrombin (50 nmol/L) and subsequently incubated with saturating concentrations of plasmaderived FVa and FXa (5 nmol/L) as detailed in Methods. A, Following fixation, platelets were stained with PE-conjugated anti-CD62P to identify activated platelets (y-axes) and specific AlexaFluor488-labeled antibodies to detect FVa (upper panel) and FXa (lower panel) binding (x-axes). The subpopulations of activated platelets that do not bind FVa or FXa (I), bind intermediate levels of FVa (II), or bind substantial amounts of FVa or FXa (high binders) (III) are indicated by their relative levels of immunostaining. The percentage of platelets binding high levels of FVa or FXa is indicated in the corresponding panel. B, Similarly prepared platelets were simultaneously labeled with anti-CD62phycoerythrin (anti-CD62P-PE), anti-FVa-Alexa Fluor 647, and anti-FXa-Alexa Fluor 488 to quantify FVa and FXa binding to the CD62 ϩ platelet population. Panels I to III indicate FXa binding; panels II and V, intermediate FVa binding; panels III and VI, high FVa binding. For confocal microscopic analyses (C), platelets were activated as described above, and cytocentrifuge specimens were prepared and visualized as described in Methods. These images represent a qualitative assessment of the ability of activated platelets to bind FVa and FXa. The laser intensity of the confocal microscope was set to a low level such that only those platelets capable of binding high levels of FVa were visualized. Shown here is a single field simultaneously immunostained with 3 different antibodies to define platelet activation (top panel), high FVa binding (middle panel), and FXa binding (bottom panel). The asterisk (*) indicates a platelet that stained for FVa and FXa, without evidence of P-selectin staining, reflecting the variance in P-selectin expression in the procoagulant population subpopulation (Supplemental Figure V) . Also indicated are a platelet that expressed high levels of FVa but did not bind FXa (arrow) and an apparent anti-FXa-Alexa Fluor 488 antibody aggregate ( †).
population. Likewise, the majority of activated platelets binding high levels of FVa (93Ϯ0.5%; nϭ6) were defined by FXa binding. A small percentage of those platelets originally defined as binding intermediate levels of FVa were able to bind FXa (meanϭ11.8Ϯ1.1%; nϭ6) ( Figure 1B , II), but these platelets represent those binding the greatest amount of FVa in that population. Likewise, a small percentage of those platelets defined as high FVa binders did not appear to bind FXa (meanϭ7.0Ϯ0.5%; nϭ6) ( Figure 1B, VI) . Similar data were obtained in 3 additional experiments, each using platelets from different donors (data not shown).
Confocal microscopic analyses of activated platelets immunostained with anti-FV#2-Cy5, anti-FXa-Alexa Fluor 488, and anti-CD62-phycoerythrin confirmed these data (Figure 1C) . A cell-by-cell comparison of these 3 images indicated that although not all activated platelets bound FVa and FXa, significant levels of FVa and FXa binding colocalized to the same subset of activated platelets, in support of the concept that, with few exceptions ( Figure 1C, arrow) , the majority of platelets expressing high levels of FVa are those that bind FXa. These combined data indicate that the assembly of a functional prothrombinase is primarily defined by a discrete subpopulation of activated platelets and, equally important, that all platelet-bound FVa molecules are not equal in their ability to support FXa binding.
Additional experiments were done to determine whether this subset of procoagulant platelets mimicked that previously reported by Alberio et al 13 Indeed, a similar subset could be generated with the simultaneous addition of low-dose thrombin (5 nmol/L) and the GPVI agonist convulxin (data not shown); however, the addition of the transglutaminase inhibitor dansylcadaverine (Յ 200 mol/L) was without effect on FVa binding to the activated platelet (Supplemental Figure  III ), suggesting a different mechanism for procoagulant subpopulation formation than that proposed by Dale et al. 15 
Characterization of the Adhesive Properties of the Procoagulant Platelet Subpopulation
Experiments were done to characterize the adhesive properties of the procoagulant platelet subpopulation capable of binding a functional prothrombinase by quantifying the membrane densities of P-selectin (CD62P) and GPIb␣ (CD42b), as well as integrins ␣ IIb (CD41) and ␤ 3 (CD61), using specific fluorophore-conjugated monoclonal antibodies (Supplemental Figure IV) . These experiments were performed in the presence of added plasma-derived FVa to define the entire population of platelets capable of binding FXa. In a representative experiment (Figure 2) , procoagulant platelets demonstrated a 5.8Ϯ1.6-fold (nϭ93) higher level of integrin ␤ 3 expression compared with those platelets unable to bind FXa. Likewise, higher levels of expression were observed for P-selectin (4.5Ϯ0.8-fold, nϭ109), integrin ␣ IIb (4.2Ϯ0.3fold, nϭ2), and GP1b␣ (6.1Ϯ2.4-fold, nϭ18) ( Table 1 ). In additional flow cytometric analyses, which simultaneously compared both FVa and FXa binding characteristics, the increased expression of P-selectin previously seen in the FXa-positive platelets was also seen in those platelets capable of binding high levels of FVa (Supplemental Figure V) , consistent with the existence of a single procoagulant platelet subpopulation expressing increased adhesive receptor density.
TO, a dye frequently used to stain nucleic acid and previously shown to identify the youngest platelets in circulation, 22 was used to evaluate the effect of platelet age on FVa and FXa binding to activated platelets, as well as adhesive receptor density expressed by activated platelets. Duallabeling studies demonstrated that 56.3Ϯ5.4% (nϭ16) of TO-positive platelets were able to bind high levels of FVa, whereas 63.2Ϯ2.8% (nϭ20) were able to bind FXa. Conversely, 75.1Ϯ5.4% (nϭ16) of platelets able to bind high levels of FVa and 68.7Ϯ3.8% (nϭ20) of platelets able to bind FXa were TO-positive. Evaluation of adhesive receptor expression as a function of platelet age demonstrated a 5.9Ϯ0.7-fold (nϭ52) higher level of P-selectin expression in the youngest (TO-positive) platelets compared with their more mature (TO-negative) counterparts ( Table 2 ). In addition, expression of integrin ␤ 3 and GPIb␣ were increased 6.0Ϯ1.0-fold (nϭ26) and 6.8Ϯ0.9-fold (nϭ26) in TOpositive platelets, respectively ( Table 2 ).
The Procoagulant Platelet Subpopulation Is Characterized by a Nondissociable Pool of Platelet-Derived FVa
During the course of these studies, observations were made indicating that a significant fraction of the membrane-bound, 
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platelet-derived FVa pool expressed subsequent to platelet activation could not be removed from the platelet membrane despite repeated washing. Thrombin-catalyzed activation of washed human platelets in the presence of RGDS and Gly-Pro-Arg-Pro, to prevent platelet aggregation and polymerization of platelet-derived fibrin, allowed repeated washing of the activated platelets, providing that RGDS was included in the wash buffers. When washing was done in the presence of EDTA to disrupt the Ca 2ϩ -dependent interaction between the FVa heavy and light chains, flow cytometric analyses using a monoclonal antibody specific for the FVa heavy chain indicated that approximately 35% of the heavy chain remained bound to the activated platelet membrane even though its interaction with the light chain had been abolished (Supplemental Figure VI) . The amount of bound light chain remained unchanged, consistent with its Ca 2ϩindependent membrane binding characteristics (data not shown). 1 Near-identical results were obtained when retention of the platelet-derived FVa heavy and light chains was assessed by Western blotting (Figure 3A and 3B) . Densitometric analyses indicated that the majority of the light chain remained associated with the platelet surface, as did Ϸ30% of the heavy chain. Thus, platelet activation resulted in the formation of a substantial, nondissociably bound pool of FVa. This nondissociably bound cofactor pool was capable of binding FXa because clotting assays indicated that 37.6Ϯ11.2% (rangeϭ14.6 to 62.0%, nϭ7) of the FVa cofactor activity remained associated with the activated platelet membrane following 5 washes ( Figure 3C ) in either the presence or the absence of Ca 2ϩ (Figure 3C, inset) . Consequently, experiments were done to determine whether and how this nondissociable pool of platelet-derived FVa contributed to the formation of the procoagulant platelet subpopulation. Flow cytometric analyses were used to quantify FVa and FXa binding to thrombin-activated platelets in the presence and absence of plasma-derived FVa. In the absence of added FVa, only the platelet-derived cofactor is expressed/bound to the activated platelet membrane, and it is defined by both nondissociable and dissociable cofactor pools, each of which is capable of binding FXa as determined by functional assays. A representative experiment (nϭ6) is shown in Figure 4 , where FVa binding is depicted in the upper histograms and FXa binding in the lower histograms. In the absence of added FVa, platelets intensely positive for FVa represented approximately 16% of the entire activated platelet population. FXa binding under identical conditions likewise represented 16% of the activated platelet population. When FVa was added to ensure saturation of all available binding sites, the percentage of platelets intensively positive for both FVa and FXa remained virtually the same (18% versus 17%), whereas the amount of bound proteins increased as indicated by the increased fluorescence associated with this population of activated platelets. These data are consistent with the formation of a single platelet subpopulation responsible for regulating functional prothrombinase assembly.
In all 6 experiments, the percentage of activated platelets binding both FVa and FXa was not significantly affected by the presence or absence of additional plasma-derived FVa, though the amount of FXa bound increased by 15% to 59% in the presence of saturating plasma-derived FVa. Differences were also observed between experiments, as the percentage of platelets representing the procoagulant subpopulation varied from as little as 8% to as much as 54% depending on the platelet donor.
Discussion
In this study, the subpopulation of activated platelets capable of regulating the functional interactions of FVa and FXa on their membrane surface was defined and characterized, under conditions ensuring maximal prothrombinase binding. Thus, the binding characteristics of FVa and FXa to thrombin-activated platelets could be unequivocally characterized, thereby extending previous studies in which it was assumed that activated platelets are homogeneous regarding their procoagulant potential. 10 The ability of thrombin-activated platelets to subsequently generate additional thrombin via a functional prothrombinase was defined by a subpopulation of predominantly "young" platelets expressing significantly increased adhesive receptor density, as well as a nondissociable pool of platelet-derived FVa in which the heavy chain of the functional cofactor is "tethered" to the platelet membrane, most likely through a GPI anchor. 23 This procoagulant platelet subpopulation was also capable of binding additional platelet-and plasma-derived FVa in a freely dissociable manner to facilitate the saturation of all available prothrombinase binding sites on the activated platelet membrane. This observation is consistent with earlier studies defining prothrombinase assembly and function in the presence and absence of added plasma-derived FVa, which indicated that the amount of platelet-derived cofactor expressed or released 
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by the activated platelet membrane is not sufficient to saturate all available prothrombinase sites. In those studies, addition of plasma-derived FVa consistently increased rates of thrombin generation by 1.2-to 3-fold, consistent with an increase in FXa binding. 24 In the same studies, saturation of the activated platelet membrane with FVa and FXa resulted in the binding of approximately 6000 molecules of FVa/platelet, whereas only 3000 molecules of bound FXa were observed, 24 suggesting that only approximately half of the platelet-bound FVa would support a FXa binding interaction. Those data are now confirmed by the identification of a subpopulation of platelets that binds FVa but does not bind FXa, and they allow us to conclude that FVa and FXa form a 1:1 complex on the procoagulant platelet membrane capable of assembling prothrombinase. Taken together, these data also confirm that the binding of FVa and FXa to the activated platelet surface is independently regulated and add to a growing body of literature that argues for the existence of activation-dependent "receptors" for FVa or FXa at the human platelet surface. 10, 25 This procoagulant platelet subpopulation demonstrated a 4to 6-fold increase in P-selectin, integrin ␤ 3 , integrin ␣ IIb , and GPIb␣ expression, thereby placing these platelets in a unique position to contribute to both hemostatic and thrombotic events, with increased adhesive receptor density guaranteeing the adhesion of these procoagulant platelets to subendothelial von Willebrand factor or von Willebrand factor released by activated endothelial cells in a number of pathological processes. Following shear-induced platelet activation, plateletderived FVa is released and expressed on the activated membrane surface. FXa, formed via the tissue factor/FVIIa complex, assembles with platelet-bound FVa to form prothrombinase and generate small amounts of thrombin, which subsequently activate more platelets. Recruitment and incorporation of procoagulant platelet subpopulations into the growing thrombus via their increased expression of ␣ IIb ␤ 3 will follow. These activated platelets also express a nondissociable, functional pool of platelet-derived FVa comprising approximately 35% to 50% of the total membrane-bound cofactor contributed by the activated platelet. Thus, this series of events will be as likely to promote thrombosis as it is to prevent hemorrhage. Likewise, the role of these platelets in the processes of wound healing, atherosclerosis, and inflammation will be favored by their increased expression of P-selectin, which will facilitate not only platelet binding to the activated endothelium but also the recruitment of monocytes/macrophages and neutrophils via their expression of P-selectin glycoprotein ligand-1. 26 Our data support the concept that not all platelets express the same procoagulant potential, a notion that is supported by several studies, [13] [14] [15] [16] [17] [18] [19] yet studies regarding prothrombinase are limited to 2 laboratories. 13, 16 Among these, the work of Kempton et al 16 indicates that platelet activation with low concentrations of thrombin and convulxin leads to the development of a platelet subpopulation capable of binding increased amounts of FV, FVIII, FIX, and FX and that increased binding of these coagulation factors is correlated with increased production of FXa and thrombin, suggesting that these platelet subpopulations describe a single procoagu-lant population capable of supporting the assembly of a functional tenase complex that will provide the FXa necessary to interact with platelet-bound FVa in prothrombinase.
Work from Dale's laboratory was the first to demonstrate that a subset of platelets activated simultaneously with low concentrations of thrombin and convulxin/collagen, termed COAT platelets, express high levels of platelet-derived FV/ FVa at their membrane surface. 13 The formation of these COAT platelets is hypothesized to occur when serotonin, released by dense granules, cross-links platelet-derived coagulation proteins, such as FV, to fibrinogen or thrombospondin bound to their receptors (␣ IIb ␤ 3 or CD36, respectively). Based on the ability of dansylcadaverine to inhibit COAT platelet formation, this cross-linking appeared to be mediated by platelet-derived FXIIIa. 15, 27 In contrast to COAT platelets, the presence of dansylcadaverine had no effect on the formation of the procoagulant platelet subpopulation described here. This is not surprising for the following reason: even though FV is a substrate for FXIIIa, 28 the glutamine residues required for the transamidation reaction are all located within the activation peptide that is released when FV is activated to FVa.
The idea that platelets are not all created equal is not restricted to the human system. 22, 29, 30 For example, Thattaliyath et al identified 2 populations of zebrafish thrombocytes distinguishable by age and lipophilicity. 22 Consistent with our data, the younger, more lipophilic thrombocytes, which appear to be responsible for the initiation of arterial thrombus formation, constitutively express a higher density of adhesive receptors and, following activation, express more P-selectin and anionic phospholipid than their more mature counterparts. 22 Considering their complexity, perhaps the heterogeneous nature of activated platelets should be expected. Platelets participate in a wide variety of physiological and pathophysiological processes. In some, thrombin generation may not be as important as the release of granular contents, which appear to be heterogeneous as well. 31, 32 Differential packaging of the ␣-granule proteins von Willebrand factor and fibrinogen allows their differential release. 32 In addition, pro-and antiangiogenic proteins appear to be organized into separate platelet granules, which are also differentially released. 31 Thus, platelets appear to express very different phenotypes and therefore are most likely under distinct hematopoietic regulation via megakaryocyte differentiation.
